Financial Times on August 27, 2009: “Increasingly westernised lifestyles amongst people in the Middle East have boosted profits at Hikma Pharmaceuticals amidst higher margins and increased sales of hypertension and diabetes drugs.“
Business Week on March 13, 2010: " Hikma Pharmaceuticals Plc has fended off seven takeover approaches in the past three years, and Chief Executive Officer Said Darwazah says he won’t consider selling the Jordanian drugmaker until it reaches a market value of 5 billion pounds ($7.7 billion)."
Mr. Eyas Qdeimat’s (Treasury Manager) article in CASH&TRADE p.16-19